Cambridge animal health technology pioneer PetMedix has clinched a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.
As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market.
The companies refuse to disclose financial details of the tie-up.
While there are many technologies that have been used to develop human therapeutic antibodies,…
Cambridge, UK, 12 January 2021: CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio’s proprietary PhysioMimix™ system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard…
Tokyo, Japan and Cambridge, UK, 12 January 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
The collaboration will combine Sosei Heptares’ world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability…
Cambridge, UK and New York City, USA, 12th January 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
Abid will lead the company’s financial, investor relations, and public relations operations, where he brings a variety of US financial experience to Artios, including a background with global public companies in corporate finance, business development, licensing, and investor relations. He joins Tania…
PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has…
Wädenswil/Zurich, Switzerland and Saffron Walden, UK, 12th January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has invested in the WAVEdelta instrument from Creoptix AG. This instrument utilizes Grating-Coupled Interferometry (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner. This system achieves superior resolution in signal and time compared to traditional Surface Plasmon Resonance (SPR) and will further strengthen Domainex’s leading position in…
Tokyo, Japan and Cambridge, UK, 11 January 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Thursday, 14 January 2021.
The presentation will begin at 10:00 a.m. Eastern Standard Time, and will be video broadcasted live in English to registered conference attendees via the Digital Conference Book. For non-attendees, an audio link to the Company’s virtual session presentation can be accessed here. Presentation slides will be…
A new way for Cambridge businesses and research institutions to connect to key sites and communities across Europe is now available thanks to Light Blue Fibre, bandwidth infrastructure provider euNetworks, and the UK Innovation Corridor’s most advanced data centre, Kao Data.
Light Blue Fibre, which was launched as a joint venture by University of Cambridge and Cambridgeshire County Council in 2019 is now being enabled by euNetworks, which specialises in data-centre-to-data-centre connectivity across the UK and Europe.
Light Blue Fibre delivers over 100km of ducting and wholesale dark fibre in…
Cambridge, UK, 11 January 2021: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a world-class research laboratory dedicated to understanding important biological processes at the molecular level, today announced an exploratory research collaboration. The project aims to develop novel protein expression systems by leveraging recent advances in direct cell reprogramming to help improve the production of proteins which are not…
With facilities already in Shanghai and Beijing, Biocair recently announced the opening of its new office in Guangzhou.
Strategically located close to Guangzhou Airport, the new office improves operational capacity, and employs a team of logistics experts with comprehensive knowledge of the local customer base, transport network and import / export regulations. Temperature-controlled vehicles will join Biocair China’s existing fleet to provide efficient, secure and compliant transportation for time and temperature-sensitive biological materials.
APAC General Manager, Kevin Xu, commented:
“…